Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | DRD3 | P35462 | 3/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6295910 | 0.90 | WRN (0.33) | DRD2DRD3OPRM1OPRD1CHRM2 | |
| SCHEMBL7141092 | 0.90 | WRN (0.33) | DRD2DRD3OPRM1OPRD1CHRM2 | |
| SCHEMBL6295877 | 0.87 | GLI1 (0.34) | OPRM1OPRD1OPRK1 | |
| SCHEMBL6295721 | 0.85 | PPIB (0.32) | DRD2 | |
| SCHEMBL6297136 | 0.82 | HTR1A (0.30) | — | |
| SCHEMBL7078899 | 0.81 | WRN (0.34) | DRD3OPRM1OPRD1OPRL1CHRM2 | |
| SCHEMBL6295927 | 0.81 | ESR1 (0.36) | DRD2DRD3OPRM1OPRD1CHRM2 | |
| SCHEMBL6301730 | 0.81 | TRPM8 (0.42) | DRD2DRD3DRD4OPRM1OPRK1 | |
| SCHEMBL6297393 | 0.81 | OPRD1 (0.32) | DRD2DRD3OPRM1OPRD1CHRM2 | |
| SCHEMBL6301624 | 0.79 | KDM4E (0.34) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171425-A1 | HIV protease inhibitors | BOYER FREDERICK EARL (US) | 2003-09-11 | — | — | US | claimed |
| US-6512006-B1 | Novel 3-position Nitrogen substituted 6,6- disubstituted-5, 6-dihydropyrones and related compounds possess antiviral properties | WARNER-LAMBERT COMPANY | 2003-01-28 | — | — | US | claimed |
| US-6927217-B2 | HIV protease inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-08-09 | — | — | US | disclosed |
| US-20030171425-A1 | HIV protease inhibitors | BOYER FREDERICK EARL (US) | 2003-09-11 | — | — | US | disclosed |
| US-6512006-B1 | Novel 3-position Nitrogen substituted 6,6- disubstituted-5, 6-dihydropyrones and related compounds possess antiviral properties | WARNER-LAMBERT COMPANY | 2003-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171425-A1 | HIV protease inhibitors | DNPEP, PRSS1, PREP | DRD2 3439/4885DRD3 2004/4885DRD4 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.